---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-009243"
form_type: "8-K"
ticker: "OCGN"
cik: "0001372299"
company_name: "Ocugen, Inc."
filed_at: "2025-03-03T23:59:59+00:00"
generated_at: "2026-05-25T17:09:21.637271+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "low"
source: SEC EDGAR
---

# Ocugen posts corporate presentation with clinical data; 6-month treated/untreated rates shown

## Summary
- Presentation shows 52% vs 44% for treated and untreated eyes at 6-month timeline.
- Data likely from OCU400 gene therapy program for retinitis pigmentosa.
- Presentation posted on company website March 3, 2025; used for investor discussions.
- No formal guidance or regulatory update provided in the filing.

## SEC filing metadata
- accession: 0001628280-25-009243
- form_type: 8-K
- ticker: OCGN
- cik: 0001372299
- company_name: Ocugen, Inc.
- filed_at: 2025-03-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372299/000162828025009243/0001628280-25-009243-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372299/000162828025009243/ocgn-20250303.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-009243
- JSON: https://secwatch.observer/filing/0001628280-25-009243.json
- Plain text: https://secwatch.observer/filing/0001628280-25-009243.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.